| Trial ID: | L6111 |
| Source ID: | NCT02443922
|
| Associated Drug: |
Glimepiride
|
| Title: |
Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Glimepiride|DRUG: Sitagliptin|DRUG: Metformin
|
| Outcome Measures: |
Primary: Beta Cell Function as measured by the mixed meal tolerance test in response to two therapies for type 2 diabetes mellitus, Up to 6 weeks|Beta Cell Function as measured by the arginine stimulation test in response to two therapies for type 2 diabetes mellitus, Up to 6 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Foundation for the National Institutes of Health | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Merck Sharp & Dohme LLC|Novartis|Pfizer|Takeda
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose:
|
| Start Date: |
2015-06
|
| Completion Date: |
2015-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-05-14
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT02443922
|
